Top Page
Sihuan Pharmaceutical Holdings Group
(0460)
Sihuan Pharmaceutical Holdings Group (0460) vs. iShares MSCI Hong Kong ETF (EWH)
Sihuan Pharmaceutical Holdings Group Business Overview & Revenue Model
Sihuan Pharmaceutical Holdings Group Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.10B | 1.90B | 1.86B | 2.18B | 3.04B | 2.46B |
| Gross Profit | 1.39B | 1.24B | 1.30B | 1.49B | 2.43B | 1.91B |
| EBITDA | -18.36M | -208.66M | 334.31M | -1.54B | 931.69M | 714.06M |
| Net Income | -80.64M | -216.66M | -54.02M | -1.91B | 416.51M | 473.38M |
Balance Sheet | ||||||
| Total Assets | 10.62B | 10.53B | 11.54B | 12.14B | 14.50B | 13.04B |
| Cash, Cash Equivalents and Short-Term Investments | 3.60B | 3.63B | 4.48B | 4.79B | 5.79B | 4.94B |
| Total Debt | 1.03B | 942.76M | 1.26B | 1.29B | 1.08B | 755.05M |
| Total Liabilities | 5.68B | 5.58B | 6.40B | 6.50B | 5.35B | 3.10B |
| Stockholders Equity | 4.38B | 4.37B | 4.43B | 4.74B | 8.28B | 9.19B |
Cash Flow | ||||||
| Free Cash Flow | 62.70M | 57.51M | -95.93M | -355.97M | 64.28M | -279.51M |
| Operating Cash Flow | 112.15M | 243.89M | 199.49M | 46.49M | 665.29M | 227.13M |
| Investing Cash Flow | 368.40M | 758.24M | 169.88M | -1.66B | -337.57M | -924.78M |
| Financing Cash Flow | -1.23B | -1.26B | -419.56M | -238.93M | 750.66M | 184.54M |
Sihuan Pharmaceutical Holdings Group Technical Analysis
Sihuan Pharmaceutical Holdings Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$13.33B | 12.44 | 25.92% | 3.93% | 19.05% | 13.68% | |
58 Neutral | HK$10.24B | 11.58 | 7.48% | 4.47% | 1.65% | -16.38% | |
54 Neutral | HK$10.83B | -37.85 | -1.26% | 3.66% | -9.58% | -128.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | HK$12.32B | -138.95 | -1.87% | 0.87% | 19.21% | -115.91% | |
41 Neutral | HK$13.81B | -61.38 | -2.79% | ― | 29.21% | 80.37% |
Sihuan Pharmaceutical Holdings Group Corporate Events
Sihuan Pharmaceutical has launched a share repurchase program under its existing mandate, buying back 8 million shares on the market at an average price of HK$1.2511 per share, equivalent to about 0.0874% of its issued share capital, with plans to hold these as treasury shares for future sale or transfer. The board frames the move as aligned with shareholder interests amid a pivotal turnaround year marked by a return to profit, stronger margins, and rapid expansion of its medical aesthetics franchise—now offering a full portfolio from botulinum toxin to aesthetic devices and expanding globally via a Swiss acquisition—alongside notable progress in its biopharmaceutical pipeline, including multiple drug approvals, NRDL inclusion, FDA Fast Track status, and the successful Hong Kong listing of subsidiary Xuanzhu Biopharm, which has boosted equity value, eased R&D funding pressure, and supports a shift into a new phase of higher-quality, growth-focused development.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group has disclosed that the trustee of its 2022 share award scheme purchased 9 million shares on the market on 18 December 2025, representing about 0.0983% of its issued share capital, at an average price of roughly HK$1.2271 per share. The board views this share purchase as a move to strengthen its equity base and incentivise its team, supporting the company’s current growth phase and long-term strategy. Management highlighted strong progress in 2025 under its dual-drive strategy of innovative drugs and global medical aesthetics expansion, including full-value-chain breakthroughs at core subsidiaries Xuanzhu Biopharm and Huisheng Biopharm—from R&D and launches to inclusion in China’s National Reimbursement Drug List—alongside rapid commercialization of self-developed regenerative medical aesthetics products and entry into the European market via its investment in Swiss firm Suisselle, developments that the company believes will enhance competitiveness, open new growth avenues, and bolster shareholder value over time.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group announced the successful renewal and inclusion of its innovative drug, Anjiuwei, in the 2025 National Reimbursement Drug List (NRDL) in China. This renewal is expected to stabilize market sales and enhance the drug’s penetration, supporting its long-term growth. Anjiuwei, developed by Xuanzhu Biopharm, a Sihuan subsidiary, is a proton pump inhibitor approved for treating duodenal ulcers. Its innovative design makes it a safer option for patients with multiple medications or renal insufficiency, filling a gap in China’s domestic market for such treatments.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. announced that its innovative drug, Bireociclib Tablets (brand name: Xuanyuening), developed by its subsidiary Xuanzhu Biopharmaceutical Co., Ltd., has been included in the National Reimbursement Drug List (NRDL) for 2025. This inclusion is expected to enhance the drug’s affordability and accessibility, significantly impacting Xuanzhu Biopharm’s market presence and sales. Bireociclib, a novel CDK2/4/6 inhibitor, offers advantages in treating advanced or metastatic breast cancer with reduced toxicity. The drug’s inclusion in the NRDL is anticipated to bolster Xuanzhu Biopharm’s long-term business development and market expansion efforts.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. announced that its subsidiary, Xuanzhu Biopharma, is considering the implementation of H share full circulation. This involves converting approximately 68.97% of its unlisted shares into H shares, pending approval from the China Securities Regulatory Commission. The move is aimed at enhancing the liquidity and marketability of Xuanzhu Biopharma’s shares, although the listing details on the Hong Kong Stock Exchange are yet to be finalized.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. has signed a cooperation agreement with U.S.-based Abalone Bio to jointly develop a new-generation innovative therapy for weight loss and muscle gain. This collaboration aims to advance research in targeting metabolism-related G protein-coupled receptors (GPCRs) to improve energy expenditure safely and effectively. The partnership leverages Abalone’s proprietary technology and Sihuan’s R&D resources to address current limitations in obesity treatments and enhance the company’s strategic position in the GPCR target field. This agreement marks a significant step in Sihuan’s strategy to deepen its involvement in the GPCR field, following its previous investment in DJS Antibodies.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. announced that its subsidiary, Xuanzhu Biopharm, has received Fast Track designation from the U.S. FDA for NG-350A, a treatment for mismatch repair-proficient locally advanced rectal cancer. This designation is significant as it expedites the development and approval process for drugs addressing unmet medical needs. NG-350A, developed in collaboration with Akamis Bio Ltd., is currently undergoing Phase Ib clinical trials and has shown promising results in safety and efficacy. This advancement strengthens Sihuan Pharmaceutical’s position in the oncology sector and highlights its commitment to addressing major clinical needs.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. announced a share repurchase of 15 million shares at an average price of HK$1.4505 per share, totaling approximately HK$21.76 million. This move is part of its strategic goal to enhance shareholder value and reflects its confidence in future growth. The company has seen significant progress in its medical aesthetics and innovative pharmaceuticals segments, with a notable revenue increase in its medical aesthetics business and the launch of several new products. These developments are expected to drive future revenue and profit growth, reinforcing Sihuan’s position in the industry.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. announced a share repurchase of 10 million shares, representing approximately 0.1089% of its total issued shares, at an average price of HK$1.5189 per share. This strategic move aligns with the company’s goal of enhancing shareholder value and reflects confidence in its future growth, particularly in its expanding medical aesthetics and innovative pharmaceuticals businesses. The company has seen significant growth in its medical aesthetics segment, with a revenue increase of 81% year-on-year, and has launched several new products, which are expected to drive future revenue and profit growth.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. announced the purchase of 9,255,000 shares as part of its 2022 Share Award Scheme, representing approximately 0.1009% of the total shares in issue. This move is part of the company’s strategic objective to strengthen its market position in the medical aesthetics and biopharmaceutical industries, potentially enhancing its operational capabilities and stakeholder value.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. has successfully completed the spin-off and separate listing of its subsidiary, Xuanzhu Biopharm, on the Main Board of the Stock Exchange of Hong Kong. The listing took place on October 15, 2025, marking a significant milestone for the company as it expands its presence in the biopharmaceutical sector, potentially enhancing its market positioning and providing new opportunities for stakeholders.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. announced the purchase of 10,000,000 shares as part of its 2022 Share Award Scheme. This transaction represents approximately 0.1089% of the total issued shares, excluding treasury shares. The purchase is part of the company’s strategic efforts to enhance its market position and align with its long-term business objectives in the pharmaceutical and medical aesthetics sectors.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. has made an equity investment in Swiss company Suisselle SA to strengthen its position in the global medical aesthetic market. This investment grants Sihuan permanent exclusive distribution rights for Suisselle’s CELLBOOSTER® skin booster products in China and enhances their collaboration to promote medical aesthetic products in Europe and other markets. The move aligns with Sihuan’s globalization strategy, complementing its previous acquisition of Genesis Biosystems in the U.S., and aims to create long-term sustainable value for shareholders.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. announced the publication of the prospectus for the proposed spin-off and separate listing of Xuanzhu Biopharm on the Main Board of the Hong Kong Stock Exchange. The global offering will include 67,333,500 H Shares, representing 13% of Xuanzhu Biopharm’s total issued share capital, with an expected offer price of HK$11.60 per share. The spin-off and listing are contingent upon approval from the Stock Exchange and market conditions, with no guarantee of proceeding, urging shareholders to exercise caution.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group has announced that its subsidiary, Meiyan Space, received approval from the National Medical Products Administration of China for its new skin booster product, Dongyan. This product, which combines hyaluronic acid sodium with L-carnosine and other components, is designed to improve skin dryness and dullness. The approval is a significant milestone for Meiyan Space, enhancing its strategic product matrix and strengthening its position in the medical aesthetics industry. The global skin booster market is projected to grow significantly, with the Chinese market expected to expand rapidly, driven by increasing consumer demand for skin health management. Meiyan Space plans to continue its investment in R&D and market penetration to provide advanced and personalized medical aesthetic services.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.